Your browser doesn't support javascript.
loading
Unleashing the Potential of 1,3-Diketone Analogues as Selective LH2 Inhibitors.
Lee, Juhoon; Guo, Hou-Fu; Wang, Shike; Maghsoud, Yazdan; Vázquez-Montelongo, Erik Antonio; Jing, Zhifeng; Sammons, Rae M; Cho, Eun Jeong; Ren, Pengyu; Cisneros, G Andrés; Kurie, Jonathan M; Dalby, Kevin N.
Affiliation
  • Lee J; Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
  • Guo HF; Targeted Therapeutic Drug Discovery and Development Program, College of Pharmacy, University of Texas, Austin, Texas 78712, United States.
  • Wang S; Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, Kentucky 40536, United States.
  • Maghsoud Y; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
  • Vázquez-Montelongo EA; Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, Texas 75080, United States.
  • Jing Z; Department of Physical Medicine and Rehabilitation, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
  • Sammons RM; Department of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.
  • Cho EJ; Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
  • Ren P; Targeted Therapeutic Drug Discovery and Development Program, College of Pharmacy, University of Texas, Austin, Texas 78712, United States.
  • Cisneros GA; Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
  • Kurie JM; Targeted Therapeutic Drug Discovery and Development Program, College of Pharmacy, University of Texas, Austin, Texas 78712, United States.
  • Dalby KN; Department of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.
ACS Med Chem Lett ; 14(10): 1396-1403, 2023 Oct 12.
Article in En | MEDLINE | ID: mdl-37849534
ABSTRACT
Lysyl hydroxylase 2 (LH2) catalyzes the formation of highly stable hydroxylysine aldehyde-derived collagen cross-links (HLCCs), thus promoting lung cancer metastasis through its capacity to modulate specific types of collagen cross-links within the tumor stroma. Using 1 and 2 from our previous high-throughput screening (HTS) as lead probes, we prepared a series of 1,3-diketone analogues, 1-18, and identified 12 and 13 that inhibit LH2 with IC50's of approximately 300 and 500 nM, respectively. Compounds 12 and 13 demonstrate selectivity for LH2 over LH1 and LH3. Quantum mechanics/molecular mechanics (QM/MM) modeling indicates that the selectivity of 12 and 13 may stem from noncovalent interactions like hydrogen bonding between the morpholine/piperazine rings with the LH2-specific Arg661. Treatment of 344SQ WT cells with 13 resulted in a dose-dependent reduction in their migration potential, whereas the compound did not impede the migration of the same cell line with an LH2 knockout (LH2KO).

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Med Chem Lett Year: 2023 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Med Chem Lett Year: 2023 Document type: Article Affiliation country: Estados Unidos